SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/306980"
 

Search: onr:"swepub:oai:gup.ub.gu.se/306980" > Clinical diagnosis ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Dubois, B. (author)

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier BV,2021

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/306980
  • https://gup.ub.gu.se/publication/306980URI
  • https://doi.org/10.1016/s1474-4422(21)00066-1DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid beta and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity. In this Personal View, the International Working Group presents what we consider to be the current limitations of biomarkers in the diagnosis of Alzheimer's disease and, on the basis of this evidence, we propose recommendations for how biomarkers should and should not be used for diagnosing Alzheimer's disease in a clinical setting. We recommend that Alzheimer's disease diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes, whereas biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Villain, N. (author)
  • Frisoni, G. B. (author)
  • Rabinovici, G. D. (author)
  • Sabbagh, M. (author)
  • Cappa, S. (author)
  • Bejanin, A. (author)
  • Bombois, S. (author)
  • Epelbaum, S. (author)
  • Teichmann, M. (author)
  • Habert, M. O. (author)
  • Nordberg, A. (author)
  • Blennow, Kaj,1958Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xbleka (author)
  • Galasko, D. (author)
  • Stern, Y. (author)
  • Rowe, C. C. (author)
  • Salloway, S. (author)
  • Schneider, L. S. (author)
  • Cummings, J. L. (author)
  • Feldman, H. H. (author)
  • Göteborgs universitetInstitutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi (creator_code:org_t)

Related titles

  • In:Lancet Neurology: Elsevier BV20:6, s. 484-4961474-4422

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view